mening
diseas
caus
inflamm
mening
caus
gener
associ
infect
present
acut
chronic
less
sever
symptom
prolong
period
acut
mening
syndrom
defin
mening
symptom
headach
neck
stiff
vomit
photophobia
conjunct
cerebr
dysfunct
confus
coma
progress
hour
day
cerebr
spinal
fluid
csf
often
present
leukocytosi
common
caus
acut
mening
unit
kingdom
bacteri
viral
infect
viral
infect
respons
asept
mening
syndrom
character
lymphocyt
pleocytosi
csf
neg
bacteri
cultur
howev
form
mening
mimick
intracellular
bacteri
infect
includ
rickettsia
spp
leptospira
spp
mycobacterium
tuberculosi
acut
viral
mening
avm
tend
occur
epidem
usual
mild
selflimit
diseas
immunocompet
patient
caus
wide
rang
viral
agent
typic
enterovirus
herpesvirus
despit
usual
mild
natur
viral
infect
also
associ
seriou
acut
viral
enceph
ave
high
mortal
rate
survivor
develop
chronic
condit
includ
signific
neurolog
deficit
acut
bacteri
mening
abm
caus
fulmin
diseas
progress
critic
lifethreaten
septicemia
extrem
rapid
high
mortal
morbid
rate
treatment
delay
withheld
caus
abm
vari
depend
immun
statu
age
patient
whether
recent
head
surgeri
trauma
preced
symptom
common
caus
healthi
adult
haemophilu
influenza
streptococcu
pneumonia
pneumococc
diseas
neisseria
meningitidi
meningococc
diseas
neonat
elderli
immunocompromis
individu
escherichia
coli
streptococcu
agalactia
gb
listeria
monocytogen
mycobacterium
tuberculosi
preval
pathogen
caus
staphylococcu
aureu
staphylococcu
epidermidi
cutibacterium
acn
caus
agent
postcrani
surgeri
csf
shunt
trauma
need
exclud
primari
diagnosi
earli
stage
diseas
etiolog
agent
respons
abm
avm
ave
extrem
difficult
diagnos
due
clinic
symptom
diffus
nonspecif
natur
therefor
empir
treatment
ceftriaxon
acyclovir
plu
minu
dexamethason
amoxicillin
administ
soon
possibl
preemptiv
isol
patient
undertaken
diagnosi
made
current
combin
predict
factor
use
form
initi
differenti
diagnosi
includ
clinic
present
csf
cell
count
biochemistri
investig
follow
csf
viral
pcr
bacteri
cultur
serolog
imag
brain
may
help
confirm
diagnosi
inform
treatment
howev
caus
agent
eg
n
meningitidi
difficult
recov
use
culturebas
method
part
due
usual
practic
administ
antibiot
prior
patient
sampl
collect
mani
diagnost
laboratori
therefor
augment
diagnost
capabl
use
molecular
method
identif
meningitisassoci
bacteri
viral
pathogen
although
implement
comprehens
primarili
realtim
qualit
polymeras
chain
reaction
assay
rtpcr
avail
limit
number
meningitisassoci
pathogen
addit
molecular
test
avail
discrimin
differ
bacteri
speci
serogroup
eg
n
meningitidi
serogroup
b
c
pneumonia
h
influenza
serogroup
meningitisassoci
strain
conduct
use
rang
method
eg
cultur
serolog
immunolog
test
refer
laboratori
latterli
sequenc
howev
still
need
harmon
methodolog
laboratori
need
develop
rapid
sensit
diagnost
method
capabl
simultan
assay
multipl
bacteri
viral
agent
discrimin
differ
strain
serogroup
facilit
develop
investig
use
microarray
solut
rapid
molecular
pathogen
identif
abm
focu
consider
attent
previou
year
rang
analyt
process
use
multiplex
analysi
system
wide
accept
previous
mean
augment
frontlin
tradit
diagnost
offer
mani
advantag
tradit
monoplex
molecular
technolog
microarray
also
highli
amen
multiplex
obviat
need
multipl
test
per
patient
potenti
save
time
cost
microarray
benefit
establish
blockbas
realtim
pcr
test
requir
less
prior
knowledg
infecti
agent
diagnost
microarray
previous
develop
detect
bacteria
virus
environment
clinic
sourc
number
group
develop
lowcomplex
diagnost
microarray
identif
microorgan
water
food
sampl
also
develop
detect
pathogen
clinic
materi
base
genu
andor
speciesspecif
oligonucleotid
probe
design
databas
gene
sequenc
align
includ
viral
bacteri
fungal
eukaryot
pathogen
wang
de
risi
colleagu
develop
number
array
detect
known
viral
emerg
viral
pathogen
use
hybrid
speciesspecif
oligonucleotid
probe
use
advanc
bioinformat
analysi
tool
reveal
pathogenspecif
signal
pattern
similar
methodolog
use
group
identifi
meningitisassoci
emerg
pathogen
includ
sever
acut
respiratori
syndrom
sar
coronaviru
present
develop
valid
mening
diagnost
microarray
reconfigur
onto
aler
arraytubetm
aler
technolog
gmbh
jena
germani
platform
provid
recommend
use
diagnost
set
bacteri
speci
strain
use
studi
shown
supplementari
materi
tabl
n
meningitidi
strain
repres
serogroup
b
c
n
flavescen
n
lactamica
strain
sourc
prof
gorring
mening
research
group
phe
porton
uk
n
meningitidi
strain
obtain
nation
collect
type
cultur
colindal
london
uk
genom
dna
neisseria
strain
purifi
follow
bacteria
cultur
overnight
hors
bloodbrain
heart
infus
agar
plate
coloni
isol
resuspend
tri
edta
glucos
teg
buffer
mm
triscl
ph
mm
edta
glucos
guanidin
hydrochlorid
lysi
buffer
guanidin
hydrochlorid
sodium
sarkinos
ad
bacteri
suspens
mix
invers
twohundr
microlit
chloroform
ad
emuls
centrifug
g
min
dna
recov
upper
aqueou
layer
precipit
ethanol
collect
centrifug
wash
twice
ethanol
dna
pellet
air
dri
resuspend
te
buffer
mm
triscl
ph
mm
edta
store
prior
use
purifi
nucleic
acid
sampl
nonmeningococc
bacteria
obtain
cowork
public
health
england
southampton
uk
phe
seven
csf
sampl
collect
initi
public
helath
england
phe
routin
test
mening
pathogen
retain
clinic
sampl
acquir
diagnost
purpos
valuabl
resourc
phe
dispens
use
anonymis
patient
materi
perform
assess
lie
outsid
human
tissu
act
accord
rcpath
guidelin
process
dna
nucleic
acid
pellet
supernat
fraction
use
modif
qiaamp
dna
mini
purif
kit
qiagen
skelton
hous
manchest
uk
follow
csf
sampl
centrifug
min
g
remov
cellular
debri
aliquot
supernat
fraction
remov
centrifug
g
min
pellet
supernat
fraction
recov
process
separ
pellet
fraction
resuspend
te
buffer
prior
process
nucleic
acid
pellet
supernat
fraction
purifi
use
qiagen
qiaamp
dna
mini
kit
accord
manufactur
instruct
recov
nucleic
acid
store
frozen
requir
human
ab
whole
blood
purchas
sigma
sigmaaldrich
dorset
uk
whole
blood
dna
purifi
use
qiaamp
dna
blood
mini
kit
qiagen
accord
manufactur
instruct
addit
csf
sampl
collect
lumbar
punctur
suspect
bacteri
viral
meningitisenceph
march
novemb
phe
volum
csf
obtain
differ
patient
sampl
therefor
phosphat
buffer
salin
pb
sigma
dorset
uk
ad
low
volum
sampl
minimum
extract
volum
make
final
total
volum
nucleic
acid
purifi
use
qiasymphoni
autom
dna
extract
platform
qiasymphoni
dsp
viruspathogen
minikit
accord
manufactur
instruct
qiagen
pathogen
human
blood
patient
dna
sampl
quantifi
spectrophotometr
analysi
nm
prior
use
oligonucleotid
probe
use
array
mixtur
sequenc
given
supplementari
materi
tabl
genusspecif
probe
design
align
rrna
sequenc
describ
previous
oligonucleotid
probe
eg
sialyltransferas
gene
n
meningitidi
design
align
bacteri
speci
strainspecif
gene
sequenc
use
clustal
w
function
either
megalign
bioedit
seventym
region
low
sequenc
conserv
select
differ
significantli
close
relat
speci
strain
discriminatori
requisit
pathogen
speci
strain
specif
probe
confirm
use
databas
search
algorithm
eg
blast
oligonucleotid
probe
greater
sequenc
ident
closelyrel
bacteri
gene
sequenc
exclud
rel
melt
temperatur
tm
probe
calcul
tm
select
suitabl
select
oligonucleotid
use
discriminatori
probe
respect
low
selfcomplementar
hairpin
loop
format
also
assess
use
algorithm
oligonucleotid
calcul
prior
inclus
array
bacteri
speci
strain
oligonucleotid
probe
glass
slide
format
microarray
synthesis
illumina
illumina
cambridg
uk
print
quadrupl
onto
epoxyco
nexterion
e
slide
schott
ltd
stafford
uk
use
biorobot
microgrid
ii
gridder
digilab
inc
hopkinton
usa
oligonucleotid
dilut
final
concentr
salinesodium
citrat
buffer
ssc
dimethyl
sulfoxid
wv
sodium
dodecyl
sulphat
prior
print
slide
airdri
bake
h
store
desicc
ambient
temperatur
dark
prior
use
glass
slide
format
microarray
slide
hybrid
amplifi
target
dna
publish
previous
minor
modif
slide
prehybrid
ssc
sd
denhardt
solut
sigmaaldrich
wash
steril
nucleasefre
water
follow
isopropyl
alcohol
airdri
randomlyamplifi
target
dna
denatur
min
dilut
final
concentr
ssc
buffer
sigmaaldrich
sd
denhardt
solut
forti
microlitr
hybrid
mix
appli
microarray
slide
cover
glass
coverslip
place
humidifi
multislid
chamber
genetix
inc
wallsend
uk
incub
h
slide
wash
follow
buffer
two
minut
ssc
sd
b
ssc
sd
c
ssc
sd
centrifug
dryness
g
min
scan
use
affymetrix
microarray
laser
scanner
gain
sixti
nonspecif
hybrid
unrel
oligonucleotid
observ
number
oligonucleotid
probe
array
use
pathogen
nonpathogen
label
nucleic
acid
address
issu
attempt
reduc
event
nonmanu
hybrid
conduct
use
advalytix
hybrid
beckman
coulter
uk
high
wycomb
uk
wash
station
addit
block
agent
ie
denhardt
solut
formamid
hybrid
buffer
reduc
background
nonspecif
hybrid
microarray
slide
prehybrid
describ
manual
hybrid
place
array
side
slideboost
hybrid
chamber
contain
sonic
agit
chip
coupl
fluid
place
slidebas
platform
accord
manufactur
instruct
lifterslip
place
slide
gasket
side
slide
left
preheat
prior
addit
label
target
preprepar
target
dna
randomlyamplifi
target
dna
denatur
min
dilut
final
concentr
ssc
sd
denhardt
solut
formamid
appli
lifterslip
edg
draw
label
target
onto
array
capillari
motion
use
platform
found
also
significantli
reduc
time
incub
need
thu
slide
incub
six
hour
maximum
mix
power
incub
slide
remov
place
chamber
wash
accord
protocol
manual
hybrid
describ
slide
centrifug
dryness
g
min
scan
use
affymetrix
microarray
laser
scanner
gain
sixti
glass
slide
array
hybrid
file
save
tiff
format
imag
captur
quantifi
use
scan
analysi
softwar
bluegnom
inc
cambridg
uk
data
normal
global
median
slide
replic
data
point
fuse
accord
median
fluoresc
intens
ident
data
logtransform
function
r
identifi
probe
significantli
higher
fluoresc
zscore
analysi
undertaken
zscore
number
standard
deviat
given
spot
intens
away
mean
therefor
measur
signal
differ
significantli
expect
valu
zi
si
zi
zscore
ith
spot
si
fluoresc
intens
ith
spot
mean
standard
deviat
sampl
spot
intens
zscore
convert
probabl
studi
probabl
valu
calcul
directli
intens
data
use
pnorm
function
r
base
packag
p
pnorm
si
probe
sort
lowest
highest
pvalu
less
userdefin
cutoff
case
consid
posit
pathogen
speci
serogroup
assign
given
test
target
base
number
signific
gener
speciesspecif
andor
serogroupposit
probe
given
rank
data
set
fluoresc
intens
raw
data
point
depict
pictori
heatmap
format
use
algorithm
written
statist
packag
r
publish
previous
microarray
hybrid
glass
slide
format
readili
amen
use
routin
diagnost
assay
limit
term
assay
set
eas
use
scaleup
highthroughput
therefor
decid
transit
best
perform
valid
detect
probe
altern
assay
format
would
amen
routin
diagnost
laboratori
use
select
prefer
best
perform
meningitisassoci
bacteri
probe
chosen
transit
onto
arraytubetm
system
use
inform
probe
perform
ascertain
prior
valid
array
glass
slide
format
focus
bacteri
mening
array
probe
set
construct
evalu
form
set
includ
probe
n
meningitidi
strain
b
c
x
l
h
influenza
agalactia
pneumonia
aureu
l
monocytogen
plu
addit
test
control
probe
pathogen
mycobacterium
tuberculosi
escherichia
coli
human
arabidopsi
thaliana
control
sequenc
supplementari
materi
tabl
dna
probe
sequenc
synthesis
print
arraytubetm
format
aler
technolog
gmbh
jena
germani
primer
target
amplif
system
design
visualomp
dnasoftwar
ann
arbor
mi
usa
use
databas
import
probe
gene
target
sequenc
softwar
provid
mean
silico
model
multiplex
amplif
step
model
process
provid
solut
ration
design
comprehens
multiplex
specif
primer
set
similar
physiochem
paramet
use
upload
gene
sequenc
refer
gene
sequenc
microarray
probe
design
exclud
bexa
newli
design
test
control
probe
upload
program
model
use
default
set
final
select
primer
pair
assess
specif
comparison
databas
sequenc
use
blast
algorithm
use
given
supplementari
materi
tabl
hplc
purifi
nucleotid
primer
synthes
eurofin
mwg
operon
ebersberg
germani
target
noncompetit
amplif
system
base
previous
publish
protocol
boland
cowork
use
amplif
label
target
nucleic
acid
studi
amplif
biotin
label
pathogen
control
human
dna
perform
use
phusion
taq
polymeras
finnzym
new
england
biolab
hitchin
uk
use
follow
amplif
protocol
phusion
taq
buffer
dntp
exclud
dutp
dutp
new
england
biolab
usa
phusion
taq
primer
mix
primer
final
concentr
dna
templat
final
volum
pcr
amplif
cycl
follow
cycl
final
step
label
target
hybrid
conduct
print
arraytubestm
use
aler
hybrid
protocol
accord
manufactur
instruct
aler
technolog
gmbh
use
polyhrp
streptavidin
fisher
scientificuk
ltd
loughborough
uk
one
minor
alter
use
final
hybrid
volum
arraytubetm
incub
perform
thermomix
comfort
microtub
shake
heater
block
eppendorf
uk
limit
stevenag
uk
read
immedi
incub
substrat
use
arraytubetm
analys
hybrid
signal
intens
data
export
analys
conduct
use
iconoclust
arraytubetm
softwar
accord
manufactur
instruct
aler
technolog
gmb
mean
intens
probe
spot
duplic
use
analysi
probe
mean
valu
consid
posit
base
valu
cutoff
establish
batchelor
colleagu
confirm
result
obtain
pathogen
target
arraytubetm
hybrid
pathogenspecif
rtpcr
assay
use
multiplex
meningitisassoci
pathogen
realtim
pcr
assay
construct
base
either
previous
publish
assay
mani
bacteri
pathogen
repres
array
eg
group
b
streptococcu
h
influenza
aureu
epidermidi
n
meningitidi
pneumonia
hous
design
phe
assay
exist
previous
publish
assay
avail
realtim
pcr
assay
meningococc
capsular
transport
gene
ctra
use
n
meningitidi
previous
describ
assay
previous
run
singleplex
howev
eas
use
assay
larg
number
sampl
reconfigur
run
three
duplex
assay
supplementari
materi
tabl
addit
assay
l
monocytogen
sourc
run
singleplex
realtim
pcr
primer
probe
synthesis
eurofin
mwg
operon
germani
taqman
univers
mastermix
kit
appli
biosystem
inc
foster
citi
ca
usa
use
per
manufactur
instruct
assay
run
abi
thermocycl
appli
biosystem
inc
foster
citi
ca
usa
assay
valid
use
purifi
speciesspecif
pathogen
nucleic
acid
prior
use
clinic
sampl
realtim
pcr
reaction
primer
use
concentr
nm
intern
label
probe
nm
taqman
univers
pcr
master
mix
appli
biosystem
inc
foster
citi
ca
usa
five
microlitr
sampl
ad
gener
total
reaction
volum
realtim
pcr
perform
reaction
plate
follow
min
min
cycl
probe
fluoresc
detect
nm
channel
assay
complet
cycl
hybrid
mening
array
use
h
influenza
strain
hpa
l
monocytogen
strain
agalactia
strain
pneumonia
strain
nctc
aureu
strain
atcc
gener
pathogenspecif
hybrid
profil
expect
figur
supplementari
materi
crosshybrid
unrel
probe
seen
sampl
includ
human
control
dna
although
pattern
cross
hybrid
rogu
probe
outlin
consist
minor
variat
crosshybrid
nonspecif
probe
differ
pathogen
dna
target
dna
target
amplifi
h
influenza
strain
hpa
gave
good
hybrid
intens
seven
eleven
speciesspecif
probe
probe
nuca
cpdb
exhibit
good
speci
specif
bexa
suggest
latter
gene
probe
use
diagnost
target
h
influenza
studi
strain
may
perhap
capsul
defici
amplifi
dna
target
l
monocytogen
strain
show
good
bind
pathogenspecif
probe
dna
target
pneumonia
bound
well
streptococcu
rrna
gener
probe
nine
twelv
specif
probe
dna
target
agalactia
strain
bound
well
streptococcu
rrna
gener
probe
seven
eight
specif
probe
dna
target
aureu
mrsa
strain
mssa
strain
exhibit
good
bind
two
sixteen
aureu
specif
probe
howev
describ
exhibit
high
degre
nonspecif
bind
bacteri
dna
target
aureu
strain
exhibit
signific
bind
n
meningitidi
serogroupspecif
probe
nonfunct
probe
pneumonia
agalactia
aureu
appear
specif
one
gene
observ
h
influenza
thu
certain
probe
nonmeningococc
meningitisassoci
pathogen
exhibit
targetspecif
hybrid
profil
show
potenti
diagnost
marker
relev
organ
probe
exhibit
minim
bind
crosshybrid
unrel
dna
target
use
futur
diagnost
develop
good
hybrid
fluoresc
intens
observ
n
meningitidisspecif
oligonucleotid
probe
neisseria
spp
amplifi
target
figur
supplementari
materi
rrna
probe
neiss
neiss
ubi
gene
probe
gave
hybrid
signal
neisseria
spp
probe
therefor
act
gener
neisseria
probe
type
iv
pilin
gene
probe
hybrid
neisseria
spp
target
pilin
gene
probe
lcba
gene
probe
show
nonspecif
bind
nonmeningococc
dna
target
nsmspp
show
bind
major
n
meningitidi
strain
dna
except
serogroup
x
z
zprime
nonmeningococc
neisseria
spp
hybrid
specif
serogroupspecif
probe
gener
correspond
well
serogroup
relev
strain
n
meningitidi
serogroup
strain
dna
target
bound
neisseria
gener
probe
serogroup
probe
exhibit
lack
specif
discuss
previous
eg
also
bound
serogroup
probe
thu
six
nine
probe
specif
design
serogroup
exhibit
group
serospecif
design
sacb
gene
remain
probe
exhibit
crossreact
bind
neisseria
spp
nonneisseri
speci
bacteri
dna
target
strain
design
z
zprime
respect
show
bind
also
bound
z
serogroupspecif
probe
show
bind
n
meningitidi
strain
target
eg
serogroup
strain
howev
also
show
bind
respect
serogroup
aspecif
probe
therefor
easili
distinguish
z
strain
z
strain
show
bind
weak
addit
bind
strain
n
meningitidi
strain
bound
gener
probe
serogroup
bspecif
probe
strain
previous
annot
strain
serogroup
specif
probe
latter
strain
therefor
previous
incorrectli
character
probe
fact
specif
serogroup
b
n
meningitidi
serogroup
c
strain
respect
show
bind
neisseria
gener
probe
four
five
serogroup
cd
probe
one
latter
probe
show
nonspecif
bind
meningitisassoci
bacteri
target
exhibit
bind
also
aureu
strain
dna
target
thu
probe
diagnost
n
meningitidi
serogroup
c
strain
serogroup
x
strain
respect
show
bind
gener
appropri
serogroupspecif
probe
addit
bound
probe
human
dna
control
show
high
degre
crossreact
bind
serogroup
w
probe
therefor
may
appear
use
signific
identifi
probe
w
strain
use
patient
clinic
sampl
directli
may
use
type
cultur
meningococc
strain
major
n
meningitidi
strain
exhibit
characterist
bind
profil
indic
serogroup
may
use
diagnost
identif
nine
eleven
n
meningitidi
strain
known
serogroup
demonstr
distinct
bind
profil
gener
serogroupspecif
probe
went
assess
nine
n
meningitidi
strain
previous
unidentifi
serogroup
view
assess
potenti
probe
serogroup
identif
figur
supplementari
materi
addit
bind
neisseria
gener
probe
n
meningitidi
strain
nctc
show
pattern
bind
indic
b
serogroup
strain
although
strain
show
limit
bind
serogroupspecif
probe
domin
profil
serogroup
b
strain
show
bind
profil
serogroup
strain
show
bind
profil
serogroup
previous
unserogroup
strain
test
could
ascrib
serogroup
microarray
hybrid
profil
howev
capsul
synthet
characterist
strain
known
pattern
bind
ident
previous
test
serogroup
strain
suggest
strainspecif
gene
sequenc
variat
ascertain
bind
profil
nonmeningococc
neisseria
strain
amplifi
dna
target
three
n
lactamica
one
n
flavescen
isol
amplifi
label
hybrid
panpathogen
array
figur
supplementari
materi
clear
bind
gener
probe
neiss
neiss
observ
n
lactamica
n
flavescen
isol
n
lactamica
strain
also
bound
also
show
crossreact
nonneisseria
spp
target
n
lactamica
bound
n
lactamica
alon
bound
therefor
addit
expect
bind
rrna
neisseriagener
probe
nonpathogen
isol
bound
neisseria
gener
probe
howev
none
bound
nsmspp
design
ctra
gene
neisseria
spp
appear
share
genet
characterist
common
pathogen
neisseria
appear
carri
type
iv
pilinlik
ubia
gene
loci
randomli
amplifi
target
seven
patient
csf
sampl
supernat
suffix
pellet
fraction
suffix
p
amplifi
label
hybrid
array
describ
control
ascertain
degre
bind
pathogenspecif
probe
nonbacteri
pathogen
target
randomli
amplifi
target
ad
dna
human
donor
whole
blood
dna
neg
control
also
hybrid
array
data
normal
global
median
rank
accord
signific
p
target
data
hybrid
depict
heatmap
format
figur
supplementari
materi
certain
sampl
produc
data
high
fluoresc
bind
intens
good
confid
eg
pathogenspecif
signal
could
ascrib
sampl
degre
confid
sampl
produc
data
low
fluoresc
bind
intens
reason
good
confid
eg
pathogenspecif
signal
could
tent
ascrib
remain
sampl
produc
data
low
fluoresc
bind
intens
low
confid
eg
pathogenspecif
signal
could
assign
put
neisseriaspecif
hybrid
profil
seen
patient
csf
sampl
howev
definit
serogroup
identif
could
made
sampl
due
incomplet
mix
serogroup
profil
show
strongest
neisseriaspecif
profil
somewhat
weaker
microarray
bind
profil
also
observ
sampl
speci
could
ascrib
streptococcicontain
sampl
due
incomplet
strain
profil
could
seen
therefor
high
degre
background
nonspecif
hybrid
obtain
use
amplifi
dna
target
patient
csf
sampl
shown
previous
identif
pathogenspecif
identif
signatur
achiev
use
highli
purifi
pathogen
nucleic
acid
observ
tent
patient
csf
dna
sampl
latter
result
may
due
part
low
abund
bacteri
dna
high
nonspecif
background
signal
contamin
host
dna
signaltonois
ratio
exist
hybrid
buffer
protocol
satisfactori
sought
improv
technic
issu
use
formamidecontain
hybrid
buffer
autom
hybrid
station
advalytix
improv
sampl
mix
hybrid
patient
csf
sampl
hybrid
mening
glass
slide
array
describ
section
sampl
ad
dna
human
donor
dna
n
lactamica
n
meningitidi
strain
serogroup
n
meningitidi
strain
serogroup
b
agalactia
amplifi
target
use
neg
posit
control
result
confirm
n
meningitidi
use
realtim
pcr
assay
ctra
gene
data
obtain
shown
figur
supplementari
materi
combin
data
hybrid
realtim
pcr
result
summaris
tabl
overal
formamidecontain
buffer
gave
lower
fluoresc
bind
intens
signal
across
probe
addit
formamid
reduc
overal
signal
intens
approxim
sevenfold
observ
overal
improv
signaltonois
ratio
nonspecif
hybrid
previous
identifi
rogu
probe
eg
greatli
reduc
n
lactamica
n
meningitidi
strain
agalactia
hybrid
gave
strong
pathogenspecif
bind
signal
specif
oligonucleotid
probe
expect
sampl
dna
data
high
fluoresc
intens
good
confid
obtain
sampl
eg
pathogenspecif
signal
could
ascrib
sampl
degre
confid
data
low
fluoresc
intens
reason
good
confid
obtain
sampl
eg
pathogenspecif
signal
could
tent
ascrib
sampl
remain
hybrid
produc
data
low
fluoresc
intens
low
confid
eg
pathogenspecif
signal
could
ascrib
sampl
degre
confid
thu
put
neisseriaspecif
hybrid
profil
seen
patient
csf
sampl
result
correspond
precis
result
realtim
pcr
n
meningitidi
ctra
five
six
real
timepcr
rtpcr
posit
sampl
correctli
identifi
although
rtpcr
neg
sampl
appear
posit
eg
discrep
may
due
fact
work
limit
detect
like
sampl
error
differ
aliquot
sampl
tent
serogroup
identif
could
made
two
neisseriacontain
sampl
serogroup
x
serogroup
cd
hybrid
serogroupspecif
probe
observ
sampl
streptococci
profil
observ
specif
speci
could
assign
sampl
clinic
sampl
larger
secondari
panel
assay
use
rtpcr
assay
common
meningitisassoci
pathogen
describ
section
result
rtpcrposit
sampl
pair
associ
cultur
result
given
tabl
eighteen
csf
sampl
one
hundr
fortysix
test
found
posit
bacteri
pathogen
rtpcr
major
found
contain
epidermidi
epidermidi
aureu
remain
sampl
found
contain
either
n
meningitidi
h
influenza
pneumonia
posit
bacteri
cultur
sampl
also
exhibit
low
ct
valu
indic
high
amount
pathogen
nucleic
acid
vi
vi
pathogen
present
pathogenspecif
primer
pair
assess
amplif
product
singleplex
analyz
use
gel
electrophoresi
data
shown
amplif
product
use
singleplex
hybrid
arraytubetm
reconfigur
mening
array
ama
confirm
correct
probe
bind
profil
target
viabl
multiplex
amplif
contain
target
primer
pair
construct
test
stage
requisit
bacteri
pathogen
dna
use
gel
electrophoresi
function
multiplex
pcr
confirm
assay
use
gener
biotinlabel
target
amplicon
hybrid
ama
tube
accord
abovedescrib
protocol
select
singl
multiplex
hybrid
profil
use
purifi
pathogen
nucleic
acid
given
figur
figur
supplementari
materi
hybrid
pattern
expect
pathogen
singl
multiplex
hybrid
reveal
hybrid
expect
amplifi
product
correct
probe
expect
howev
multiplex
hybrid
reveal
nonspecif
bind
rogu
probe
eg
nsmapp
number
nonspecif
hybrid
event
seen
previous
use
glass
slide
print
array
appear
technic
issu
function
multiplex
amplif
target
appar
platform
independ
hybrid
rogu
probe
also
observ
use
neg
control
dna
signal
could
filter
use
baselin
test
hybrid
profil
data
analys
probe
remov
array
addit
formamid
glass
slide
configur
array
remov
background
crosshybrid
therefor
surmis
due
secondari
structur
bind
event
unknown
origin
microarray
hybrid
target
amplifi
bacteri
rtpcrposit
clinic
csf
tabl
clinic
sampl
neg
control
hybrid
given
supplementari
materi
summaris
tabl
select
hybrid
sampl
figur
ten
twenti
clinic
csf
sampl
gave
result
concord
rtpcr
assay
confirm
n
meningitidi
posit
three
strain
identifi
serogroup
one
serogroup
b
confirm
epidermidi
addit
streptococci
pp
confirm
pneumonia
posit
h
influenza
posit
group
b
streptococci
posit
interestingli
show
hybrid
pattern
indic
pneumonia
addit
expect
epidermidi
signal
may
indic
mix
infect
pneumonia
signal
detect
use
rtpcr
clear
signal
could
seen
use
microarray
hybrid
display
hybrid
pattern
h
influenza
thu
appear
incomplet
correl
rtpcr
microarray
hybrid
result
microarray
may
detect
pathogen
signal
sampl
detect
use
rtpcr
vice
versa
may
due
sampl
error
studi
describ
develop
use
mening
diagnost
microarray
specif
meningitisassoci
pathogen
detect
molecular
serogroup
previous
identifi
strain
n
meningitidi
molecular
serogroup
previous
unassign
strain
previous
develop
panpathogen
microarray
base
conserv
speciesspecif
bacteri
viral
sequenc
shown
capabl
specif
pathogen
identif
use
amplifi
fluoresc
label
target
use
discrimin
closelyrel
bacillu
spp
part
develop
extend
capabl
panpathogen
array
design
probe
set
detect
five
signific
abm
pathogen
n
meningitidi
h
influenza
agalactia
pneumonia
aureu
l
monocytogen
bacteri
speci
also
includ
probe
would
discrimin
n
meningitidi
serogroup
b
c
w
x
z
valid
abm
probe
set
glass
slide
format
use
previous
publish
random
amplif
method
initi
conduct
order
valid
pathogenspecif
probe
use
method
limit
bia
toward
known
target
amplif
test
control
nucleic
acid
result
present
conclud
meningitisassoci
oligonucleotid
probe
set
show
clear
specif
hybrid
pattern
use
randomlyamplifi
pathogen
nucleic
acid
manual
hybrid
method
formamidefre
buffer
consist
pathogenspecif
profil
observ
nonmeningococc
meningococc
pathogen
mani
design
probe
evid
strain
differ
one
strain
test
small
number
specif
probe
function
well
discuss
show
nonspecif
bind
number
unrel
dna
target
nonspecif
hybrid
signal
could
correct
use
human
dna
control
howev
gener
use
diagnost
probe
use
hybrid
protocol
format
howev
limit
method
reduc
sensit
ie
within
mix
pool
nucleic
acid
ie
pathogen
host
clinic
csf
sampl
target
interest
may
low
concentr
amplif
subsequ
hybrid
nucleic
acid
amplifi
equal
mix
pool
reduc
hybrid
signal
specif
target
interest
oligonucleotid
probe
array
reduc
overal
sensit
detect
ascertain
whether
could
due
part
due
poor
mix
hybrid
triall
use
advalytix
slideboost
hybrid
station
without
addit
formamid
contain
buffer
investig
whether
could
amelior
technic
issu
pathogenspecif
profil
obtain
h
influenza
agalactia
pneumonia
aureu
l
monocytogen
n
meningitidi
strain
test
probe
set
therefor
valuabl
detect
relev
organ
neisseria
group
probe
show
bind
mani
bacteri
dna
target
eg
hybrid
nonpathogen
neisseria
spp
target
eg
pilinrel
protein
probe
suggest
homologu
neisseria
strain
examin
howev
serogroupspecif
probe
highli
discriminatori
found
correctli
identifi
previous
serogroup
strain
ascrib
serogroup
previous
ungroup
strain
profil
inform
would
use
determin
serogroup
meningococc
strain
previou
serogroup
assign
group
conduct
similar
studi
swiderek
et
al
use
dna
microarray
multilocu
sequenc
type
n
meningitidi
coreless
et
al
character
variou
n
meningitidi
isol
use
resequenc
dna
microarray
lin
use
resequenc
array
identifi
rang
differ
respiratori
tract
pathogen
previou
work
also
demonstr
util
microarray
serogroup
bacteri
pathogen
eg
e
coli
shigella
spp
streptococci
spp
genotyp
variou
pathogen
associ
infect
detect
antibiot
resist
gene
salmonella
spp
aureu
therefor
microarray
proven
util
detect
simultan
strain
profil
meningitisassoci
speci
strain
addit
function
nonpathogen
neisseria
spp
includ
commens
n
lactamica
show
bind
profil
neisseria
gener
rrna
probe
probe
studi
ie
identifi
neisseria
gener
probe
nonpathogen
neisseria
spp
therefor
share
gene
similar
pathogen
n
meningitidi
strain
group
shown
gener
high
degre
gene
conserv
among
neisseria
isol
even
gene
consid
associ
pathogen
type
iv
pilinrel
protein
shown
present
mani
neisseria
spp
includ
n
meningitidi
serogroup
b
n
gonorrhoea
nonpathogen
strain
n
lactamica
thu
proport
neisseria
probe
identifi
util
identif
neisseria
spp
addit
subset
specif
identif
pathogen
n
meningitidi
strain
meningitisassoci
probe
set
shown
correctli
identifi
pathogenspecif
profil
use
highli
purifi
pathogen
nucleic
acid
target
view
futur
implement
technolog
routin
diagnost
tool
wish
establish
whether
method
could
use
identifi
pathogen
signal
csf
sampl
patient
suspect
mening
randomlyamplifi
label
target
purifi
csf
nucleic
acid
hybrid
array
use
formamidefre
manual
hybrid
method
recognis
pathogen
signal
detect
eight
fourteen
csf
sampl
test
amplifi
label
human
nucleic
acid
crosshybrid
signific
degre
certain
pathogen
probe
eg
n
meningitidi
w
x
serogroupspecif
probe
although
background
hybrid
signal
sampl
high
signaltonois
ratio
poor
hybrid
pattern
consist
number
experi
patient
csf
target
reamplifi
hybrid
number
occas
similar
result
consist
obtain
result
like
due
presenc
background
host
nucleic
acid
rel
low
rel
concentr
pathogen
nucleic
acid
sampl
evidenc
high
ct
valu
obtain
use
realtim
pcr
assay
suggest
concentr
pathogen
dna
sampl
limit
diagnost
test
like
oper
limit
detect
improv
signal
resolut
obtain
use
improv
data
analysi
method
andor
background
correct
use
human
dna
control
discuss
previous
howev
presenc
human
nucleic
acid
sampl
probabl
still
occlud
diminishingli
small
pathogen
signal
due
overwhelm
abund
amplifi
target
similar
observ
made
use
human
patient
sampl
materi
bacteri
viral
panpathogen
array
consequ
group
develop
complex
bioinformat
approach
resolv
pathogen
microarray
signal
complex
mix
host
pathogen
nucleic
acid
rel
simpl
method
data
correct
hybrid
control
describ
use
resolv
pathogenspecif
signal
csf
clinic
sampl
howev
work
would
requir
improv
efficaci
hybrid
format
method
use
clinic
context
addit
improv
data
analysi
method
sought
improv
hybrid
protocol
reduc
nonspecif
background
improv
signal
resolut
crosshybrid
event
number
hybrid
refin
evalu
experiment
attempt
improv
signaltonois
ratio
includ
prehybrid
hybrid
block
use
trna
salmonsperm
mous
human
dna
twocolour
hybrid
use
either
human
mous
amplifi
dna
target
second
channel
none
treatment
desir
effect
improv
pathogenspecif
signal
addit
presenc
ad
foreign
dna
found
block
hybrid
probe
design
highli
conserv
gene
good
fluoresc
intens
previous
obtain
eg
rrna
probe
altern
evalu
addit
formamid
exist
hybrid
buffer
hybrid
use
autom
hybrid
station
advalytix
slideboostertm
variou
differ
protocol
tri
includ
vari
formamid
concentr
incub
time
data
shown
howev
found
formamid
vv
six
hour
incub
maximum
mix
speed
gave
optim
result
pathogen
clinic
dna
target
hybrid
dna
target
patient
csf
sampl
control
without
dna
human
donor
dna
control
n
lactamica
n
meningitidi
strain
agalactia
hybrid
array
use
revis
protocol
addit
formamid
hybrid
buffer
found
significantli
improv
resolut
specif
signal
hybrid
target
autom
hybrid
method
experi
appear
reduc
nonspecif
bind
improv
signaltonois
ratio
pathogenspecif
signal
could
seen
number
clinic
sampl
detect
readili
background
compar
result
obtain
use
manual
hybrid
despit
overal
lower
signal
intens
pathogen
signal
detect
ten
fourteen
pellet
supernat
csf
sampl
test
clear
recognis
signal
neisseria
speci
four
ten
streptococci
one
ten
sampl
test
although
neisseria
spp
profil
seen
could
ascrib
precis
strain
serogroup
indic
serogroupspecif
profil
seen
sampl
serogroup
x
serogroup
cd
howev
main
fluoresc
intens
target
bind
serogroupspecif
probe
n
meningitidi
csf
amplifi
target
lower
gener
probe
eg
may
reflect
natur
gene
probe
design
gene
present
multicopi
eg
rrna
gene
other
present
singl
copi
hybrid
signal
singl
copi
number
gene
includ
serotyp
n
meningitidi
strain
weaker
multicopi
gene
strain
n
meningitidi
contain
gene
capsul
biosynthesi
would
therefor
readili
type
use
either
gene
protein
capsul
marker
addit
strain
may
exhibit
phase
variat
capsul
outer
membran
protein
gene
caus
difficulti
classic
serotyp
diagnosi
outbreak
strain
strain
would
still
detect
typeabl
use
microarray
short
improv
hybrid
specif
use
formamidebas
buffer
advalytix
slideboost
hybrid
station
howev
technic
issu
still
remain
reflect
microarray
method
may
suitabl
use
frontlin
diagnost
assay
without
protocol
refin
array
also
refocus
transfer
platform
aler
technolog
gmbh
jena
germani
evalu
use
develop
high
throughput
frontlin
diagnost
system
fulli
develop
amen
routin
highthroughput
use
glass
slide
format
lower
densiti
microarray
offer
viabl
altern
screen
multipl
target
simultan
simpl
highthroughput
system
rapid
use
inexpens
reagent
would
fit
seamlessli
clinic
laboratori
system
triall
confirmatori
qpcr
assay
run
parallel
abm
target
use
publish
laboratori
develop
assay
transfer
focus
array
arraytubetm
format
success
proof
concept
evalu
use
purifi
pathogen
nucleic
acid
known
posit
patient
csf
sampl
show
promis
clear
serotyp
profil
obtain
suspect
n
meningitidi
strain
target
amplif
system
appear
reduc
nonspecif
background
hybrid
signal
human
contamin
nucleic
acid
thu
overcom
problem
encount
use
random
amplif
method
similar
technic
issu
aris
previou
hybrid
protocol
format
observ
also
particular
nonspecif
hybrid
certain
probe
occur
consist
sampl
pair
neg
control
futur
use
remov
rogu
probe
would
rel
straightforward
either
data
process
physic
array
paramet
true
posit
explor
batchelor
et
al
use
reliabl
method
set
cutoff
valu
enabl
data
process
identif
signific
pathogen
probe
profil
colorimetr
detect
protocol
also
faster
effici
would
allow
higherthroughput
sampl
process
detect
critic
featur
use
within
clinic
set
although
sensit
issu
remain
low
pathogen
concentr
evidenc
high
realtimepcr
ct
valu
modif
protocol
includ
target
amplif
system
abm
microarray
format
show
promis
diagnost
tool
within
clinic
set
use
panbacteri
mening
array
could
facilit
simultan
detect
divers
target
negat
use
multipl
separ
assay
lead
improv
time
result
comparison
molecular
diagnost
test
howev
limit
output
correspond
precis
obtain
rtpcr
format
show
promis
parallel
rapid
detect
meningitiscaus
pathogen
howev
develop
work
would
requir
summari
aim
develop
diagnost
test
hybrid
system
base
gener
amplif
target
would
requir
prior
knowledg
organ
would
slant
bia
toward
known
pathogen
view
establish
method
could
use
either
multiplex
pathogenspecif
predesign
array
set
gener
array
noncogn
array
develop
schrenzel
colleagu
mani
group
design
microarray
detect
pathogen
clinic
environment
sampl
howev
main
util
method
amplifi
hybrid
specif
pcr
product
complementari
pathogenspecif
probe
repres
array
fluchip
microarray
detect
influenza
viru
one
exampl
microarray
type
alreadi
valid
use
routin
diseas
diagnosi
similar
technolog
includ
resequenc
array
shown
use
identif
pathogen
recombin
microarray
detect
novel
virus
may
adapt
autom
highthroughput
pathogen
detect
although
chose
deliber
use
randomamplif
method
reduc
bia
gener
target
materi
may
contain
unknown
pathogen
limit
method
amplifi
nucleic
acid
sampl
well
pathogen
present
overal
array
use
randomlyamplifi
target
show
good
util
detect
pathogenspecif
signal
use
purifi
pathogen
nucleic
acid
less
effici
use
clinic
csf
sampl
materi
due
technic
limit
outlin
transfer
arraytubetm
platform
format
use
specif
amplif
method
show
best
potenti
respect
gener
pathogen
specif
signal
requisit
specif
sensit
hybrid
requir
routin
diagnost
tool
abil
assay
rapid
effici
specif
sensit
essenti
establish
robust
assay
routin
use
array
may
use
context
without
consider
protocol
refin
howev
would
requir
extens
optim
present
time
use
like
limit
speci
strain
type
cultur
within
laboratori
set
could
use
improv
detect
divers
target
mening
laboratori
set
use
purifi
pathogen
nucleic
acid
similar
aler
arraytubetm
system
detect
type
pathogen
test
may
facilit
rapid
speci
strain
design
thu
improv
time
diagnosi
improv
clinic
outcom
similar
type
assay
develop
use
loopmedi
isotherm
amplif
method
howev
run
independ
singletub
reaction
present
current
lack
multiplex
capac
valid
mening
microarray
glass
slide
format
use
randomli
amplifi
dna
target
without
use
formamidecontain
buffer
success
howev
technic
issu
nonfunct
crosshybrid
probe
bacteri
human
dna
control
target
long
complex
hybrid
protocol
readili
amen
highthroughput
limit
use
ongo
develop
array
format
repurpos
array
onto
aler
arraytubetm
format
use
target
amplif
system
fruit
clear
pathogenspecif
signal
could
seen
pathogen
dna
clinic
csf
sampl
hybrid
would
lend
use
routin
diagnost
tool
laboratori
set
use
purifi
pathogen
nucleic
acid
addit
capabl
n
meningitidi
serogroup
identif
